What's in It for Me? Contextualizing the Potential Clinical Impacts of Lecanemab, Donanemab, and Other Anti-β-amyloid Monoclonal Antibodies in Early Alzheimer's Disease

Jin, M., & Noble, J. M. (2024). What’s in It for Me? Contextualizing the Potential Clinical Impacts of Lecanemab, Donanemab, and Other Anti-β-amyloid Monoclonal Antibodies in Early Alzheimer’s Disease. Eneuro, 11(9), ENEURO.0088-24.2024. https://doi.org/10.1523/eneuro.0088-24.2024
Authors:
Michelle Jin
James M Noble
Affiliated Authors:
Michelle Jin
James M Noble
Columbia Affiliation:
Subjects:
Alzheimer Disease (MeSH)
Amyloid beta-Peptides (MeSH)
Antibodies, Monoclonal (MeSH)
Author Keywords:
alzheimer’s disease
clinical efficacy
donanemab
lecanemab
minimal clinically important difference
alzheimer's disease
elink
Publication Type:
Article
Unique ID:
10.1523/eneuro.0088-24.2024
PMID:
39332901
DOI:
10.1523/eneuro.0088-24.2024
Journal:
ENeuro
Publication Date:
Data Source:
PubMed
Source Link:
View PubMed Record
View Scopus Record
View Web of Science Record

Record Created: